

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

## Cannabidiol for treating seizures caused by tuberous sclerosis complex ID1416

## Provisional stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• GW Pharmaceuticals (cannabidiol)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Brain and Spine Foundation</li> <li>• Brain Charity</li> <li>• British Institute of Learning Disabilities</li> <li>• British Lung Foundation</li> <li>• Epilepsy Action</li> <li>• Foundation for People with Learning Disabilities</li> <li>• Genetic Alliance UK</li> <li>• Joint Epilepsy Council</li> <li>• MENCAP</li> <li>• Neurological Alliance</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• S.T.A.B.L.E (Supporting those Affected by Lifelong Epilepsy)</li> <li>• SUDEP Action</li> <li>• Sue Ryder</li> <li>• Tuberous Sclerosis Association</li> <li>• Young Epilepsy</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of British Neurologists</li> <li>• Association of Genetic Nurses &amp; Counsellors</li> <li>• British Geriatrics Society</li> <li>• British Neuropathological Society</li> <li>• British Paediatric Epilepsy Group</li> <li>• British Society for Gene and Cell Therapy</li> <li>• British Society for Genetic Medicine</li> <li>• Epilepsy Nurses Association</li> <li>• Epilepsy Society</li> <li>• Institute of Neurology</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Cell and Gene Therapy Catapult</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• Neurological Alliance of Scotland</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Wales Neurological Alliance</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> <li>• Accord Healthcare (lamotrigine, levetiracetam, topiramate)</li> <li>• Actavis (clobazam)</li> <li>• Atnahs Pharma (clobazam)</li> <li>• Aurobindo Pharma (lamotrigine, levetiracetam, topiramate)</li> <li>• Beacon Pharmaceuticals (levetiracetam)</li> <li>• Bowmed Ibisqus (levetiracetam)</li> <li>• Consilient Health (levetiracetam)</li> <li>• Desitin Pharma (levetiracetam, sodium valproate)</li> </ul>

Provisional stakeholder list for the technology appraisal of cannabidiol for treating seizures caused by tuberous sclerosis complex ID1416

Issue date: April 2021

© National Institute for Health and Care Excellence 2021. All rights reserved Page 1 of 3

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• International League Against Epilepsy UK</li> <li>• Neuromodulation Society of UK and Ireland</li> <li>• Primary Care and Community Neurology Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Genetic Testing Network</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• NHS Great Yarmouth &amp; Waveney CCG</li> <li>• NHS Islington CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• GlaxoSmithKline (lamotrigine)</li> <li>• Glenmark Pharmaceuticals (levetiracetam, topiramate)</li> <li>• Hospira (levetiracetam)</li> <li>• Intrapharm Laboratories (levetiracetam)</li> <li>• Janssen (topiramate)</li> <li>• Martindale Pharma (clobazam)</li> <li>• Mylan (carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, topiramate)</li> <li>• Novartis (carbamazepine, oxcarbazepine)</li> <li>• Rivopharm (levetiracetam)</li> <li>• Rosemont Pharmaceuticals (clobazam, levetiracetam, topiramate)</li> <li>• Sanofi (clobazam, sodium valproate)</li> <li>• Scieure Pharma (levetiracetam)</li> <li>• Sun pharma (levetiracetam)</li> <li>• Thame Laboratories (clobazam, levetiracetam)</li> <li>• UCB Pharma (levetiracetam)</li> <li>• Wockhardt (levetiracetam, sodium valproate)</li> <li>• Zentiva (sodium valproate)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Brain Research UK</li> <li>• British Neurological Research Trust</li> <li>• Cochrane Cystic Fibrosis &amp; Genetic Disorders Group</li> <li>• Cochrane Epilepsy Group</li> <li>• Epilepsy Research UK</li> <li>• Genomics England</li> <li>• MRC Clinical Trials Unit</li> <li>• National Hospital for Neurology and Neurosurgery</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.